Moneycontrol PRO
Upcoming Webinar:Prashant Shah explains ‘Irrelevance of Bull & Bear Markets for Success in Technical Analysis’. Register For Free!

Buy Abbott India: target of Rs 19,065: ICICI Direct

ICICI Direct is bullish on Abbott India recommended buy rating on the stock with a target price of Rs 19,065 in its research report dated November 11, 2020.

November 12, 2020 / 06:09 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Abbott India

Q2FY21 results were a mixed bag. While margins, profitability were better than our estimates, revenues were lower due to slowdown in some therapeutic areas due to extended lockdown and lower footfalls at clinics. Revenues remained muted at Rs 1054 crore. EBITDA margins expanded 344 bps YoY to 22.8%, mainly due to 253 bps improvement in gross margins to 45.5% and lower other expenditure. EBITDA grew 17.7% to Rs 240.4 crore. Net profit grew a mere 1.1% YoY to Rs 180.4 crore. Delta vis-à-vis EBITDA was mainly due to higher tax rate (25.9% against 17.5% in Q2FY20).


We continue to believe in Abbott’s strong growth track in power brands and capability of new launches on a fairly consistent basis (+100 launches in the last ten years). We maintain BUY and arrive at a target price of Rs 19065 based on 40x FY23 EPS of Rs 476.6.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Nov 12, 2020 06:09 pm

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark